3M Company filed a Form 8-K with the SEC on September 10, 2026, disclosing the closing of a three-tranche euro-denominated debt offering totaling €1,500,000,000 in aggregate principal amount.
Hertz Global Holdings, Inc. and The Hertz Corporation filed a Form 8-K on September 10, 2026, disclosing two executive appointments made effective September 9, 2026, in connection with the company's new Platform Operating Model.
Director Laura K. Thompson filed a Form 4 with the SEC on September 10, 2026, reporting the sale of 160 shares of Parker-Hannifin Corp common stock on September 8, 2026.
Nancy M. Vu, Executive Vice President, General Counsel and Secretary of Park Hotels & Resorts Inc., filed a statement of changes in beneficial ownership on September 10, 2026, reporting an acquisition of common stock on September 3, 2026.
Parker-Hannifin Corporation filed a Current Report on Form 8-K with the SEC on September 10, 2026, disclosing the pricing of two concurrent senior note offerings totaling $2.4 billion in U.S. dollar-denominated notes and €2.025 billion in euro-denominated notes, with proceeds intended to repay borrowings …
Lyell Immunopharma, Inc. filed a Form 8-K on September 10, 2026, disclosing the completion of a technology transfer for its LYL273 product candidate to the company's LyFE Manufacturing Facility in Bothell, Washington, along with an updated timeline for the ongoing Phase 1/2 clinical trial …
Jill C. Olander, Executive Vice President of Human Resources at Park Hotels & Resorts Inc. (NYSE:PK), reported the acquisition of 66,312 restricted shares of common stock on September 3, 2026, in a filing submitted to the SEC on September 10, 2026.
Anavex is a clinical-stage biotechnology company listed on theNasdaqunder AVXL, developing oral small-molecule therapies for central-nervous-system disorders. Its lead candidate, blarcamesine (ANAVEX2-73), a sigma-1 receptor agonist, is being advanced for early Alzheimer's disease, with additional programs in Rett syndrome and Fragile X syndrome.
Akebia Therapeutics is a biopharmaceutical company focused on kidney disease, listed on theNasdaqunder AKBA. Its commercial portfolio is anchored by Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia due to chronic kidney disease in adults on dialysis, alongside Auryxia, an established phosphate-binder product now …
Upstream Bio is developing verekitug, a monoclonal antibody that blocks the receptor for thymic stromal lymphopoietin (TSLP), an upstream driver of inflammation implicated across respiratory disease. On September 1, 2026, the company announced pivotal Phase 3 development plans for verekitug in both severe asthma …